Cite
HARVARD Citation
Terauchi, Y. et al. (2020). Benefits of the fixed‐ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time‐to‐control analysis of the LixiLan JP phase 3 trials. Diabetes, obesity & metabolism. pp. 35-47. [Online].